ERBB2 and neoplasm: Our results enrich the already available data of real-time liquid biopsy and encourage the screening of tdEVs for treatment targets in clinics, since they seem to better reflect the HER2 phenotype of the primary tumor than CTCs opening the path towards a more rational and objective choice of the patients who will or will not be subjected to HER2 targeting therapies.